Larimar Therapeutics, Inc. - 8-K Filing

Larimar Therapeutics completes rolling BLA submission for nomlabofusp seeking accelerated approval for Friedreich’s ataxia. (Items: 2.02 Results of Operations and Financial Condition, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $LRMR

Read the full article at SEC EDGAR

More Regulatory news